AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: FLGT
Report Date: 2026-07-31
Full Report: https://amaly.io/stock/FLGT

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Fulgent Genetics, Inc. (FLGT) operates in the healthcare diagnostics sector, providing genetic and molecular testing services that align with Shariah principles on permissible business activities. Financial screening reveals compliance in debt and income ratios but failure in liquidity due to excessive cash holdings exceeding thresholds across standards. The company is not included in any major Shariah indices, leading to an overall non-compliant status. Purification is required at 2.6% for non-permissible income elements. Investors should monitor liquidity management for potential future compliance.

Primary Compliance Concerns:
- Liquidity ratio exceeds 30-33% thresholds across AAOIFI, MSCI, and S&P standards
- High cash and interest-bearing securities relative to market cap

Purification Requirement: 2.60%
Index Inclusion: Not included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, or Dow Jones Islamic Market (DJIM).

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 1.2%
Liquidity Ratio: 50.0%
Interest Income Ratio: 2.6%
Purification Required: 2.60%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-01

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-27T12:00:00Z

---
Full interactive report: https://amaly.io/stock/FLGT
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.